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Abstract: The synthesis of ()-5-[(4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-
dioxolan-4-yl]-2,2-dimethyl-4,7-dihydro-1,3-dioxepine is reported. Product character-
ization was carried out by IR, 
1
H NMR, 
13
C NMR, MS, elemental analysis and  
optical rotation.  
Keywords: polyoxygenated compounds; acetonide; allylic diol 
 
Acetals are frequently used as protecting groups for carbonyl groups in organic synthesis mainly 
due to their stability towards hydrolysis by bases [1]. As well as being remarkable synthetic building 
blocks, cyclic acetals are also important in nature. For instance, the most stable form of glucose in 
solution is its cyclic hemiacetal, maltose is an acetal made from two glucose units, and acetaldehyde 
diethyl acetal is an important flavouring compound in distilled beverages [2]. Pharmaceutical industry 
has also commercialized a number of bioactive acetonide-containing bioactive products such as 
fluocinolone acetonide or triamcinolone acetonide, which are potent corticosteroids primarily used in 
dermatology to reduce skin inflammation [3]. 
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Herein, we report the synthesis of ()-5-[(4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-
4-yl]-2,2-dimethyl-4,7-dihydro-1,3-dioxepine (2) by refluxing the corresponding allylic diol 1 in 
acetone for 24 h (Scheme 1). Chiral precursor 1 was prepared by reduction of the appropriate 
butenolide as reported previously [4].  
Scheme 1.  
OO
OHHO
O
1
OO
O
O O
p-TsOH
acetone
reflux, 24 h
2 (87% yield)
 
Experimental 
General 
1
H and 
13
C NMR spectra were recorded at 25 °C on a Bruker Avance 500 spectrometer in CDCl3 as 
solvent, and chemical shifts are reported relative to Me4Si ( = 0). Low- and high-resolution mass 
spectra were obtained by using a Micromass VG Autospec spectrometer. Elemental analysis was 
performed on a Fisons Instrument EA 1108 CHNS-O analyzer. Infrared spectra were recorded on a 
Bruker IFS 55 spectrophotometer on compounds dispersed on a NaCl disc. Optical rotations 
were determined for solutions in chloroform with a Perkin Elmer 343 polarimeter using a sodium lamp 
(589 nm). Thin-layer chromatography was carried out on Merck aluminium sheets coated with silica 
gel 60 F254. Compounds were visualized by use of 254 nm UV light and/or phosphomolybdic acid  
20 wt.% solution in ethanol with heating. All solvents were purified by standard techniques [5]. Flash 
chromatography was performed on Merck silica gel 60 (0.0400.063 mm, 230400 mesh 
ASTM).  Anhydrous magnesium sulfate was used for drying solutions.  
Synthesis of ()-5-[(4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-4,7-
dihydro-1,3-dioxepine (2): To a stirred solution of allylic diol 1 (308 mg, 1.0 mmol) in acetone  
(25 mL), p-toluenesulfonic acid (p-TsOH) (3 mg, 0.017 mmol) was added at room temperature. The 
reaction mixture was refluxed for 24 h, until the TLC analysis showed that no starting material was 
present. The solvent was concentrated and the residue diluted with Et2O (30 mL) and washed with a 
5% solution of NaHCO3. The combined organic phases were dried (MgSO4), filtered, concentrated, 
and the residue purified by silica gel column chromatography, eluting with AcOEt:n-hexane 10:90. 
Product 2 (303 mg, 87% yield) was obtained as a colourless oil: 25D = 12.3 (c 0.70, CHCl3);  
1
H NMR (400 MHz, CDCl3) /ppm = 1.43 (s, 12H), 3.56 (dd, J = 5.2, 10.6 Hz, 1H), 3.63 (dd, J = 3.1, 
10.6 Hz, 1H), 3.95 (ddd, J = 3.1, 5.2, 8.6 Hz, 1H), 4.22−4.30 (m, 4H), 4.36−4.40 (m, 1H), 4.57 (d,  
J = 12.0 Hz, 1H), 4.63 (d, J = 12.0 Hz, 1H), 5.61 (m, 1H), 7.28−7.37 (m, 5H); 13C NMR (100 MHz, 
CDCl3) /ppm = 23.8 (q), 26.9 (q), 60.0 (t), 60.8 (t), 69.4 (t), 73.5 (t), 78.4 (d), 80.1 (d), 102.1 (s), 
109.2 (s), 127.6 (d), 127.7 (d), 128.3 (d), 128.5 (d), 137.3 (s), 137.9 (s); FT-IR (thin film) max (cm
-1
) 
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2987, 2933, 2862, 1373, 1218, 1088, 870, 738; MS (EI+) m/z (relative intensity %) 348 (M
+
, 1.3), 333 
([M–CH3]
+
, 1.2), 290 (4.7), 2.75 (2.4), 260 (4.2), 91 (100); HRMS (EI+) exact mass calculated for 
C20H28O5 (M
+
) m/z 348.1931, found m/z 348.1937. Elemental analysis calculated for C20H28O5:  
C, 68.94; H, 8.10; found: C, 68.74; H, 7.68. 
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